XML 43 R33.htm IDEA: XBRL DOCUMENT v3.25.3
Financial Instruments (Narrative) (Details)
 3 Months Ended 9 Months Ended
Sep. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
Dec. 31, 2024
USD ($)
Sep. 02, 2020
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Realized investment gains (losses) $ 0 $ 0 $ 0 $ 0    
Change in fair value of contingent consideration     2,390,000 (12,170,000)    
Current portion of contingent consideration 18,730,000   18,730,000   $ 0  
Ascyrus Medical LLC            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Percentage of outstanding equity acquired           100.00%
Maximum amount of future consideration payment           $ 100,000,000.0
Change in fair value of contingent consideration 2,600,000 $ 3,500,000 2,400,000 $ (12,200,000)    
Business combination, contingent consideration, liability 55,300,000   55,300,000   $ 52,900,000  
Current portion of contingent consideration 18,700,000   18,700,000      
Ascyrus Medical LLC | Contingent Payment Upon PMA Approval            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Business combination, contingent consideration, liability $ 25,000,000.0   $ 25,000,000.0      
Ascyrus Medical LLC | Measurement Input, Discount Rate            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Contingent consideration, measurement input 0.17   0.17